PLXNC1 and hepatocellular carcinoma: The present study therefore investigated the responses of HCC cells to sorafenib and lenvatinib treatment on the Plexin C1 axis and explored the potential of Plexin C1 as a molecular marker for assessing the sensitivity of HCC to MKI treatment.